Liminatus Pharma, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Liminatus Pharma, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Debt, after subtracting cash, equals 26% of its market value (net debt). Lower than 87% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-6.9×Operating cash was negative last year, while some debt falls due within a year.
Higher than 56% of Healthcare companies in United States.
Cash Cushion Ratio
−26%Debt, after subtracting cash, equals 26% of its market value (net debt).
Lower than 87% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Liminatus Pharma, Inc. made a loss over the last year. Liminatus Pharma, Inc. owes $0.91 for every $1 it owns. Liminatus Pharma, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossLiminatus Pharma, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
13.14The share price is 13.14 times Liminatus Pharma, Inc.'s book value per share, higher than 89% of Healthcare companies in United States.
Market cap
$4 MThe total market value of all of Liminatus Pharma, Inc.'s shares at today's price (share price × number of shares), smaller than 95% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$0 MWhat Liminatus Pharma, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.22Net worth divided by the number of shares. The share price of $2.94 is 13.1 times this, which is the P/B above.
Owes vs Owns
0.91×Liminatus Pharma, Inc. owes $0.91 for every $1 it owns (high), higher than 83% of Healthcare companies in United States.
Dividend yield
NoneLiminatus Pharma, Inc. does not currently pay a dividend.
Profit growth
LossLiminatus Pharma, Inc. made a loss in each of the last two years.
Interest cover
Not coveredLiminatus Pharma, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net debtLiminatus Pharma, Inc. had $1 M more debt than cash (net debt) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Liminatus Pharma, Inc.: $4 M ÷ $0 M (30 Jun 2026) = 13.1.
How much does Liminatus Pharma, Inc. owe compared with what it owns?
Liminatus Pharma, Inc. owes $0.91 for every $1 it owns (high), higher than 83% of Healthcare companies in United States.
Does Liminatus Pharma, Inc. pay a dividend?
No. Liminatus Pharma, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.